Pediatric Medical Nutrition Therapy
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Prevalence of Fructose Malabsorption in Patients with Irritable Bowel Syndrome After Excluding Small Intestinal Bacterial Overgrowth
J Neurogastroenterol Motil, Vol. 24 No. 2 April, 2018 pISSN: 2093-0879 eISSN: 2093-0887 https://doi.org/10.5056/jnm17044 JNM Journal of Neurogastroenterology and Motility Original Article Prevalence of Fructose Malabsorption in Patients With Irritable Bowel Syndrome After Excluding Small Intestinal Bacterial Overgrowth Kee Wook Jung,1 Myeognsook Seo,1 Young Hwan Cho,1 Young-Ok Park,2 So-Yoon Yoon,2 Jungbok Lee,3 Dong-Hoon Yang,1 In Ja Yoon,1 So Young Seo,1 Hyo Jeong Lee,1 Sang Hyoung Park,1 Kyung Jo Kim,1 Byong Duk Ye,1 Jeong-Sik Byeon,1 Hwoon-Yong Jung,1 Suk-Kyun Yang,1 Jin-Ho Kim,1 and Seung-Jae Myung1* Departments of 1Gastroenterology, 2Clinical Nutrition, and 3Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Background/Aims Fructose malabsorption (FM) mimics symptoms of irritable bowel syndrome (IBS), and its prevalence has increased. Diagnosing FM in IBS is challenging because of its overlap with small intestinal bacterial overgrowth (SIBO). We assessed the prevalence of FM by comparing patients with IBS with asymptomatic control individuals after excluding SIBO using the glucose hydrogen breath test (HBT). Methods Patients diagnosed with IBS and asymptomatic control individuals were enrolled prospectively. Dietary habits were assessed with the Food Frequency Questionnaire. After excluding SIBO, participants underwent HBTs with both 15 g and 25 g of fructose. Results Thirty-five patients with IBS and 35 age- and sex-matched asymptomatic control individuals were enrolled. The 15-g fructose HBT yielded positive results in 7 of the 35 (20.0%) patients with IBS and in 2 of 35 (5.7%) controls (P = 0.070). -
Limiting Fructose, Fructans Intake May Ease IBS
36 Digestive Disorders FAMILY P RACTICE N EWS • July 1, 2008 Limiting Fructose, Fructans Intake May Ease IBS BY MARY ANN MOON “marked and sustained global improve- of irritable bowel syndrome (IBS) in patients prove symptoms. In the current study, the Contributing Writer ment in gastrointestinal symptoms,” re- who also have fructose malabsorption. researchers focused on osmotic load with- searchers noted. A subsequent study of The results also demonstrate that re- in the lumen and fermentative gas content. atients with irritable bowel syn- the patients revealed that symptom relief stricting intake of these substances may Poorly absorbed short-chain carbohy- drome and fructose malabsorption was not specific to restricted intake of lead to durable symptomatic improve- drates, including fructose and lactose, are Pappeared to benefit from a diet that fructose, but was achieved by limiting the ment, wrote Ms. Shepherd, a dietician at highly fermentable. They exert a strong restricted intake of fructose and fructans, intake of poorly absorbed short-chain Australia’s Monash University, Clayton, osmotic effect in people who have malab- Susan J. Shepherd and her colleagues re- carbohydrates. Victoria, and her colleagues. sorption of these two sugars—about 40% ported in an article appearing in the July These findings “represent the first high- They theorized that, because many ab- of the population in the case of fructose, 2008 issue of Clinical Gastroenterology level evidence” that poorly absorbed short- dominal symptoms may originate from and between 15% to 100% of the popula- and Hepatology. chain carbohydrates—fructose and fruc- bowel distension, addressing factors that tion for lactose. In the 25-patient study, the diet led to tans—are dietary triggers for the symptoms contribute to the distension would im- To minimize or eliminate intake of poor- ly absorbed short-chain carbohydrates, the investigators created a diet that omitted Brief Summary—see package insert for full prescribing information. -
Oxalate Loading Test: a Screening Test for Steatorrhoea
Gut: first published as 10.1136/gut.20.12.1089 on 1 December 1979. Downloaded from Gut, 1979, 20, 1089-1094 Oxalate loading test: a screening test for steatorrhoea D. S. RAMPTON', G. P. KASIDAS, G. ALAN ROSE, AND MARTIN SARNER2 From University College Hospital, London, St. Peter's Hospitals and Institute of Urology, London SUMMARY To investigate the possibility of measuring urinary oxalate output instead of faecal fat excretion as an outpatient screening test for steatorrhoea, we determined 24 hour urinary oxalate and five day faecal fat excretion before and during an oral load of sodium oxalate 600 mg daily (oxalate 4-44 mmol), in 32 patients with suspected malabsorption on a diet containing oxalate 30 mg (0-33 mmol), fat 50 g (180 mmol), and calcium 1 g (25 mmol). Nineteen patients proved to have steatorrhoea (mean faecal fat 62 mmol/24 h, range 19-186 mmol) of varying aetiologies. On the diet alone, urinary oxalate was raised in only nine of these patients (mean 0 25 mmol/24 h, range 0-08-059 mmol) (normal <0 20). By contrast, when the diet was supplemented with oral sodium oxalate, all 19 patients with steatorrhoea had hyperoxaluria (mean 0-91 mmol/24 h, range 046- 1P44 mmol) (normal <0-44). There was a significant positive linear relationship between urinary oxalate and faecal fat when the 32 patients were on the high oxalate intake (r=0*73, P <0.001), but not when they were on the low oxalate intake. Mean percentage absorption of orally administered oxalate was 58+09% (±1 SD) in normal subjects and 14-7+6-0% (P <0.002) in patients with steatorrhoea. -
16. Questions and Answers
16. Questions and Answers 1. Which of the following is not associated with esophageal webs? A. Plummer-Vinson syndrome B. Epidermolysis bullosa C. Lupus D. Psoriasis E. Stevens-Johnson syndrome 2. An 11 year old boy complains that occasionally a bite of hotdog “gives mild pressing pain in his chest” and that “it takes a while before he can take another bite.” If it happens again, he discards the hotdog but sometimes he can finish it. The most helpful diagnostic information would come from A. Family history of Schatzki rings B. Eosinophil counts C. UGI D. Time-phased MRI E. Technetium 99 salivagram 3. 12 year old boy previously healthy with one-month history of difficulty swallowing both solid and liquids. He sometimes complains food is getting stuck in his retrosternal area after swallowing. His weight decreased approximately 5% from last year. He denies vomiting, choking, gagging, drooling, pain during swallowing or retrosternal pain. His physical examination is normal. What would be the appropriate next investigation to perform in this patient? A. Upper Endoscopy B. Upper GI contrast study C. Esophageal manometry D. Modified Barium Swallow (MBS) E. Direct laryngoscopy 4. A 12 year old male presents to the ER after a recent episode of emesis. The parents are concerned because undigested food 3 days old was in his vomit. He admits to a sensation of food and liquids “sticking” in his chest for the past 4 months, as he points to the upper middle chest. Parents relate a 10 lb (4.5 Kg) weight loss over the past 3 months. -
Chronic Pancreatitis: What the Clinician Want to Know from Mri
HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Magn Reson Manuscript Author Imaging Clin Manuscript Author N Am. Author manuscript; available in PMC 2019 August 01. Published in final edited form as: Magn Reson Imaging Clin N Am. 2018 August ; 26(3): 451–461. doi:10.1016/j.mric.2018.03.012. CHRONIC PANCREATITIS: WHAT THE CLINICIAN WANT TO KNOW FROM MRI TEMEL TIRKES, M.D. Department of Radiology and Clinical Sciences, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA Keywords Pancreas; Chronic Pancreatitis; Magnetic Resonance Imaging; Magnetic Resonance Cholangiopancreatography; Computerized Tomography INTRODUCTION Chronic pancreatitis (CP) is a low prevalence disease.1–3 In 2006, there were approximately 50 cases of definite CP per 100,000 population in Olmsted County, MN 3, translating to a total of 150,000–200,000 cases in the US population. Clinical features of CP are highly variable and include minimal, or no symptoms of debilitating pain repeated episodes of acute pancreatitis, pancreatic exocrine and endocrine insufficiency and pancreatic cancer. CP profoundly affects the quality of life, which can be worse than other chronic conditions and cancers.4 Natural history studies for CP originated mainly from centers outside the U.S.5−910,11 conducted during the 1960–1990’s and consisted primarily of males with alcoholic CP. Only one large retrospective longitudinal cohort study has been conducted in the US for patients seen at the Mayo Clinic from 1976–1982.12 While these data provide general insights into disease evolution, it is difficult to predict the probability of outcomes or disease progression in individual patients. -
The Practice of Gastrointestinal Motility Laboratory During COVID-19 Pandemic
J Neurogastroenterol Motil, Vol. 26 No. 3 July, 2020 pISSN: 2093-0879 eISSN: 2093-0887 https://doi.org/10.5056/jnm20107 JNM Journal of Neurogastroenterology and Motility Review The Practice of Gastrointestinal Motility Laboratory During COVID-19 Pandemic: Position Statements of the Asian Neurogastroenterology and Motility Association (ANMA-GML-COVID-19 Position Statements) Kewin T H Siah,1,2* M Masudur Rahman,3 Andrew M L Ong,4,5 Alex Y S Soh,1,2 Yeong Yeh Lee,6,7 Yinglian Xiao,8 Sanjeev Sachdeva,9 Kee Wook Jung,10 Yen-Po Wang,11 Tadayuki Oshima,12 Tanisa Patcharatrakul,13,14 Ping-Huei Tseng,15 Omesh Goyal,16 Junxiong Pang,17 Christopher K C Lai,18 Jung Ho Park,19 Sanjiv Mahadeva,20 Yu Kyung Cho,21 Justin C Y Wu,22 Uday C Ghoshal,23 and Hiroto Miwa12 1Department of Medicine, Yong Loo Lin School of Medicine, The National University of Singapore, Singapore; 2Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore; 3Department of Gastroenterology, Sheikh Russel National Gastroliver Institute and Hospital, Dhaka, Bangladesh; 4Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore; 5Duke-NUS Medical School, Singapore; 6School of Medical Sciences, Universiti Sains Malaysia, Malaysia; 7St George and Sutherland Clinical School, University of New South Wales, Kogarah, NSW, Australia; 8Department of Gastroenterology and Hepatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; 9Department of Gastroenterology, GB Pant Hospital, New Delhi, India; -
Blueprint Genetics Primary Hyperoxaluria Panel
Primary Hyperoxaluria Panel Test code: KI0801 Is a 3 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of hyperoxaluria. About Primary Hyperoxaluria The primary hyperoxalurias are rare disorders of glyoxylate metabolism, which result in markedly increased endogenous oxalate synthesis by the liver. They are characterized by an excess of oxalate resulting in manifestations ranging from occasional renal stones, recurrent nephrolithiasis and nephrocalcinosis to end-stage renal disease (ESRD) and systemic oxalosis. Presenting ranges from the neonatal period to adulthood. Among disorders causing hyperoxaluria, the primary hyperoxalurias are the most severe, ultimately leading to ESRD and if untreated, death in most patients. Type I primary hyperoxaluria (PH1), is caused by deficient or absent activity of liver-specific peroxisomal alanine glyoxylate aminotransferase (AGT). In some patients with PH1 type disease, the enzyme is present but mistargeted to mitochondria where it is metabolically inactive. The severe infantile form is characterized by a failure to thrive, nephrocalcinosis with or without nephrolithiasis and early ESRD. Onset in childhood and adolescence is often characterized by recurrent urolithiasis (with or without nephrocalcinosis) and progressive renal failure. The late onset form is characterized by occasional renal stones with onset in adulthood, but acute renal failure caused by bilateral obstruction of the kidneys by oxalate stones may occur. Other manifestations include urinary tract infections, dysuria and hematuria. The ongoing systemic oxalosis also may lead to other clinical manifestations such as cardiac conduction defects, vascular calcification with distal gangrene, disturbed vision, specific brown colored retinal deposits, skin nodules, joint involvement and bone disease leading to fractures in long-term dialysis-dependent patients. -
Redalyc.The Nutritional Limitations of Plant-Based Beverages in Infancy
Nutrición Hospitalaria ISSN: 0212-1611 [email protected] Sociedad Española de Nutrición Parenteral y Enteral España Vitoria, Isidro The nutritional limitations of plant-based beverages in infancy and childhood Nutrición Hospitalaria, vol. 34, núm. 5, 2017, pp. 1205-1214 Sociedad Española de Nutrición Parenteral y Enteral Madrid, España Available in: http://www.redalyc.org/articulo.oa?id=309253341026 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Nutr Hosp. 2017; 34(5):1205-1214 ISSN 0212-1611 - CODEN NUHOEQ S.V.R. 318 Nutrición Hospitalaria Revisión The nutritional limitations of plant-based beverages in infancy and childhood Limitaciones nutricionales de las bebidas vegetales en la lactancia y la infancia Isidro Vitoria Unit of Nutrition and Metabolopathies. Hospital Universitario y Politécnico La Fe. Valencia, Spain Abstract Breastfeeding, infant formula and cow’s milk are basic foods in infant nutrition. However, they are being increasingly replaced either totally or partially by plant-based beverages. The composition of 164 plant-based beverages available in Spain was reviewed based on the nutritional labeling of the package and the man- ufacturers’ webpages. This was compared to the composition of cow’s milk and infant formula. In addition, the nutritional disease associated with consumption of plant-based beverages in infants and children was reviewed by means of a literature search in Medline and Embase since 1990 based on the key words “plant-based beverages” or “rice beverages” or “almond beverages” or “soy beverages” and “infant” or “child”. -
Navigating Home Care: Parenteral Nutrition—Part Two
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #11 Series Editor: Carol Rees Parrish, M.S., R.D., CNSD Navigating Home Care: Parenteral Nutrition—Part Two by Gisela Barnadas Parenteral nutrition (PN) is often used for patients who are unable to absorb suffi- cient nutrition through the gastrointestinal tract. PN can be safely administered in the home setting with proper assessment and monitoring of the patient. An interdiscipli- nary team approach is used to identify and avoid potential complications, which may occur. This article provides the physician with specific guidelines for evaluating, ordering and monitoring PN therapy in the home patient. It also addresses financial and reimbursement considerations with emphasis on understanding the often con- fusing, Medicare guidelines. CASE 1 • What resources are available to help manage this JR is a 65-year-old female with vascular disease, patient in the home? hypertension, diabetes and history of a hysterectomy. • What resources are there available for the patient? She presents with severe abdominal pain, vomiting and • Will insurance pay for this? diarrhea. A small bowel series documents a bowel obstruction, most likely due to bowel ischemia. Find- Providing total parenteral nutrition in the home ings during surgical intervention included: twisted, (HPN) is by no means a new treatment option. The gangrenous small bowel with multiple adhesions first record of a patient receiving HPN was a 36-year- resulting in resection of her distal jejunum, ileum and old woman with extensive metastatic ovarian carci- right colon, leaving an intact duodenum, approximately noma in 1968.(1) While the exact number of people 100 cm of the jejunum and most of her left colon. -
Fructose As an Endogenous Toxin
HEPATOCYTE MOLECULAR CYTOTOXIC MECHANISM STUDY OF FRUCTOSE AND ITS METABOLITES INVOLVED IN NONALCOHOLIC STEATOHEPATITIS AND HYPEROXALURIA By Yan (Cynthia) Feng A thesis submitted in the conformity with the requirements for the degree of Master of Science Graduate Department of Pharmaceutical Sciences University of Toronto © Copyright by Yan (Cynthia) Feng 2010 ABSTRACT HEPATOCYTE MOLECULAR CYTOTOXIC MECHANISM STUDY OF FRUCTOSE AND ITS METABOLITES INVOLVED IN NONALCOHOLIC STEATOHEPATITIS AND HYPEROXALURIA Yan (Cynthia) Feng Master of Science, 2010 Department of Pharmaceutical Sciences University of Toronto High chronic fructose consumption is linked to a nonalcoholic steatohepatitis (NASH) type of hepatotoxicity. Oxalate is the major endpoint of fructose metabolism, which accumulates in the kidney causing renal stone disease. Both diseases are life-threatening if not treated. Our objective was to study the molecular cytotoxicity mechanisms of fructose and some of its metabolites in the liver. Fructose metabolites were incubated with primary rat hepatocytes, but cytotoxicity only occurred if the hepatocytes were exposed to non-toxic amounts of hydrogen peroxide such as those released by activated immune cells. Glyoxal was most likely the endogenous toxin responsible for fructose induced toxicity formed via autoxidation of the fructose metabolite glycolaldehyde catalyzed by superoxide radicals, or oxidation by Fenton’s hydroxyl radicals. As for hyperoxaluria, glyoxylate was more cytotoxic than oxalate presumably because of the formation of condensation product oxalomalate causing mitochondrial toxicity and oxidative stress. Oxalate toxicity likely involved pro-oxidant iron complex formation. ii ACKNOWLEDGEMENTS I would like to dedicate this thesis to my family. To my parents, thank you for the sacrifices you have made for me, thank you for always being there, loving me and supporting me throughout my life. -
Short Bowel Syndrome with Intestinal Failure Were Randomized to Teduglutide (0.05 Mg/Kg/Day) Or Placebo for 24 Weeks
Short Bowel (Gut) Syndrome LaTasha Henry February 25th, 2016 Learning Objectives • Define SBS • Normal function of small bowel • Clinical Manifestation and Diagnosis • Management • Updates Basic Definition • A malabsorption disorder caused by the surgical removal of the small intestine, or rarely it is due to the complete dysfunction of a large segment of bowel. • Most cases are acquired, although some children are born with a congenital short bowel. Intestinal Failure • SBS is the most common cause of intestinal failure, the state in which an individual’s GI function is inadequate to maintain his/her nutrient and hydration status w/o intravenous or enteral supplementation. • In addition to SBS, diseases or congenital defects that cause severe malabsorption, bowel obstruction, and dysmotility (eg, pseudo- obstruction) are causes of intestinal failure. Causes of SBS • surgical resection for Crohn’s disease • Malignancy • Radiation • vascular insufficiency • necrotizing enterocolitis (pediatric) • congenital intestinal anomalies such as atresias or gastroschisis (pediatric) Length as a Determinant of Intestinal Function • The length of the small intestine is an important determinant of intestinal function • Infant normal length is approximately 125 cm at the start of the third trimester of gestation and 250 cm at term • <75 cm are at risk for SBS • Adult normal length is approximately 400 cm • Adults with residual small intestine of less than 180 cm are at risk for developing SBS; those with less than 60 cm of small intestine (but with a -
Nutrition Options in Short-Bowel Syndrome Upmcphysicianresources.Com/GI Instructions: Services
In This Issue 1 Nutrition Options in Short-Bowel Syndrome SPRING 2017 Division of Gastroenterology, 3 Gastric Carcinoids with Duodenal Ulcers Hepatology, and Nutrition 4 Living Donor Liver Transplant (LDLT) 6 PancreasFest 2017 / Honors and Awards 7 Pittsburgh Gut Club 8 What Is This? Nutrition Options in Short-Bowel Syndrome By David G. Binion, MD, and Zachary Zator, MD Intestinal transplantation is an option for select patients with short-bowel syndrome- associated intestinal failure (SBS-IF) who fail or do not tolerate nutritional rehabilitation. There are a range of factors to consider in the nutritional management of patients before and after intestinal transplantation. SBS-IF can be defined as the inability to maintain proper nutritional balance — including of proteins, electrolytes, macronutrients, micronutrients, and fluids — while adhering to a conventional diet in the face of an anatomically or functionally limited gut surface. The ideal management of patients with SBS-IF involves a multidisciplinary team of gastro enterologists, nurses, dietitians, pharmacists, and surgeons. Pharmacotherapeutic agents aimed at minimizing fluid losses have been routinely employed to support these patients. For instance, antidiarrheal agents, such as loperamide or diphenoxylate, are used alongside proton pump inhibitors. Somatostatin analogs, like octreotide, inhibit gastrointestinal secretions from the stomach, pancreas, and intestines and have been proven beneficial in the past. However, their role can be limited, as somatostatin can actually